Published in J Virol on November 01, 1994
Efficient intracellular assembly of papillomaviral vectors. J Virol (2004) 5.36
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36
Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol (1997) 2.29
Papillomavirus capsid binding and uptake by cells from different tissues and species. J Virol (1995) 2.24
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol (1995) 2.13
The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J Virol (1998) 2.12
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol (1996) 1.94
Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol (2003) 1.82
Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells. J Virol (1995) 1.70
Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J Virol (2009) 1.69
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68
Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol (1997) 1.66
Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol (1999) 1.66
Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol (1996) 1.66
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest (2001) 1.63
Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J Virol (2005) 1.61
Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A (1998) 1.59
Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol (2008) 1.49
Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol (2002) 1.48
Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology (2011) 1.48
Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J Virol (2001) 1.44
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol (2002) 1.35
Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol (2009) 1.35
L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation. J Virol (2001) 1.34
Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol (1995) 1.32
A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis (2011) 1.31
Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A (1999) 1.31
A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells. Proc Natl Acad Sci U S A (2001) 1.29
Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection. J Virol (2001) 1.28
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25
In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol (1998) 1.20
A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope. J Virol (1997) 1.20
Aberrant expression of homeobox gene HOXA7 is associated with müllerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response. Proc Natl Acad Sci U S A (2001) 1.05
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes. Virology (2009) 0.98
Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18. J Virol (2007) 0.97
Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications. Expert Rev Mol Med (2010) 0.96
High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One (2013) 0.93
Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsid. Virology (2010) 0.93
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol (2013) 0.92
Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. J Clin Microbiol (2002) 0.91
Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity. PLoS Pathog (2014) 0.91
Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. J Immunol (2006) 0.90
Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions. Clin Vaccine Immunol (2007) 0.88
Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies. Clin Vaccine Immunol (2007) 0.87
Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope. BMC Microbiol (2004) 0.85
Immunoprevention of human papillomavirus-associated malignancies. Cancer Prev Res (Phila) (2014) 0.84
Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation. PLoS One (2013) 0.84
Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS One (2011) 0.83
Alpha-defensin HD5 inhibits furin cleavage of human papillomavirus 16 L2 to block infection. J Virol (2014) 0.83
Study of infectious virus production from HPV18/16 capsid chimeras. Virology (2010) 0.78
Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies. J Transl Med (2010) 0.77
Papillomavirus assembly: An overview and perspectives. Virus Res (2016) 0.75
Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiol Mol Biol Rev (2016) 0.75
Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies. Curr Protoc Microbiol (2015) 0.75
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem J (1973) 22.93
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
A quantitative in vitro focus assay for bovine papilloma virus. Virology (1980) 7.14
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12
Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology (1992) 2.53
Interaction of papillomaviruses with the cell surface. J Virol (1994) 2.44
Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol (1990) 2.34
Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol (1990) 2.26
The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology (1991) 2.24
Genital human papillomavirus infection. Proc Natl Acad Sci U S A (1994) 2.12
Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts. Int J Cancer (1991) 1.98
Identification of L2 open reading frame gene products of bovine papillomavirus type 1 using monoclonal antibodies. J Gen Virol (1989) 1.30
Identification of the bovine papillomavirus L1 gene product using monoclonal antibodies. Virology (1988) 1.23
Neutralization of CRPV infectivity by monoclonal antibodies that identify conformational epitopes on intact virions. Virus Res (1991) 1.19
Monoclonal antibody neutralization of BPV-1. Virus Res (1993) 1.08
Induction of plasmacytomas secreting antigen-specific monoclonal antibodies with a retrovirus expressing v-abl and c-myc. Proc Natl Acad Sci U S A (1991) 0.93
Induction of plasmacytomas that secrete monoclonal anti-peptide antibodies by retroviral transformation. J Immunol Methods (1994) 0.92
Recombinant peptides as immunogens: a comparison of protocols for antisera production using the pGEX system. Biotechniques (1992) 0.89
Mechanism of activation of a human oncogene. Nature (1982) 12.09
Mouse cells transformed by bovine papillomavirus contain only extrachromosomal viral DNA sequences. Proc Natl Acad Sci U S A (1981) 9.27
Murine leukemia virus: high-frequency activation in vitro by 5-iododeoxyuridine and 5-bromodeoxyuridine. Science (1971) 8.78
The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature (1981) 8.44
Helper-independent transformation by unintegrated Harvey sarcoma virus DNA. J Virol (1978) 7.75
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
A quantitative in vitro focus assay for bovine papilloma virus. Virology (1980) 7.14
In vitro tumorigenic transformation by a defined sub-genomic fragment of bovine papilloma virus DNA. Nature (1980) 6.67
HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J (1989) 6.60
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33
Identification of a second transforming region in bovine papillomavirus DNA. Proc Natl Acad Sci U S A (1984) 5.88
Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA. Nature (1987) 5.61
Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci U S A (1981) 5.51
Cellular origin and role of mink cell focus-forming viruses in murine thymic lymphomas. Nature (1982) 5.23
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12
Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature (1982) 5.08
Transfection of molecularly cloned Friend murine leukemia virus DNA yields a highly leukemogenic helper-independent type C virus. J Virol (1980) 4.91
Molecular cloning of infectious integrated murine leukemia virus DNA from infected mouse cells. Proc Natl Acad Sci U S A (1980) 4.71
Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus. J Virol (1980) 4.63
Origin of mink cytopathic focus-forming (MCF) viruses:comparison with ecotropic and xenotropic murine leukemia virus genomes. Virology (1981) 4.62
Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science (1988) 4.58
Virus-specific transcription in bovine papillomavirus-transformed mouse cells. Virology (1982) 4.52
Qualitative and quantitative studies of AKR-type murine leukemia virus sequences in mouse DNA. Cold Spring Harb Symp Quant Biol (1975) 4.49
The p21 ras C-terminus is required for transformation and membrane association. Nature (1984) 4.43
Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J (1984) 4.28
Genomes of murine leukemia viruses isolated from wild mice. J Virol (1981) 4.24
Structure of endogenous murine leukemia virus DNA in mouse genomes. Proc Natl Acad Sci U S A (1980) 4.24
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
Long terminal repeat of murine retroviral DNAs: sequence analysis, host-proviral junctions, and preintegration site. J Virol (1982) 4.06
E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene. J Virol (1986) 4.04
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst (1994) 3.95
Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science (1987) 3.93
Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: initial structural and biological characterization. J Virol (1979) 3.90
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
Mapping of heavy chain genes for mouse immunoglobulins M and D. Science (1980) 3.61
Immediate and subsequent growth responses of maize leaves to changes in water status. Plant Physiol (1971) 3.58
Virus infection of murine teratocarcinoma stem cell lines. Cell (1977) 3.54
Definitive evidence that the murine C-type virus inducing locus Akv-1 is viral genetic material. Proc Natl Acad Sci U S A (1975) 3.51
Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci U S A (1982) 3.48
Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell (1992) 3.30
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Characterization of a human colon/lung carcinoma oncogene. Nature (1983) 3.26
Identification of the protein encoded by the E6 transforming gene of bovine papillomavirus. Science (1985) 3.21
The transforming function of bovine papillomavirus DNA. Proc Natl Acad Sci U S A (1983) 3.19
Translation of open reading frame E5 of bovine papillomavirus is required for its transforming activity. Proc Natl Acad Sci U S A (1986) 3.17
Mammalian and yeast ras gene products: biological function in their heterologous systems. Science (1985) 3.03
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J Virol (1989) 3.01
Maize leaf elongation: continuous measurements and close dependence on plant water status. Science (1970) 2.98
Evidence that the AKR murine-leukemia-virus genome is complete in DNA of the high-virus AKR mouse and incomplete in the DNA of the "virus-negative" NIH mouse. Proc Natl Acad Sci U S A (1974) 2.95
AKR murine leukemia virus genome: frequency of sequences in DNA of high-, low-, and non-virus-yielding mouse strains. Proc Natl Acad Sci U S A (1974) 2.91
Nucleotide sequence of the 3' end of MCF 247 murine leukemia virus. J Virol (1983) 2.87
Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J (1987) 2.84
Mutational analysis of a ras catalytic domain. Mol Cell Biol (1986) 2.76
The specific DNA recognition sequence of the bovine papillomavirus E2 protein is an E2-dependent enhancer. EMBO J (1988) 2.66
Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem (1993) 2.62
Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med (1990) 2.62
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J (1990) 2.57
Two modes of c-myb activation in virus-induced mouse myeloid tumors. Mol Cell Biol (1986) 2.57
The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors. Cell (1989) 2.52
Functional organization of the Harvey murine sarcoma virus genome. J Virol (1980) 2.46
Interaction of papillomaviruses with the cell surface. J Virol (1994) 2.44
Diurnal growth trends, water potential, and osmotic adjustment of maize and sorghum leaves in the field. Plant Physiol (1979) 2.43
The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res (1988) 2.42
DNA rearrangement and altered RNA expression of the c-myb oncogene in mouse plasmacytoid lymphosarcomas. Science (1983) 2.40
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev (2001) 2.38
On the pathogenesis of Semliki forest virus (SFV) infection in the hamster. Br J Exp Pathol (1967) 2.32
Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution. Nat Struct Biol (1997) 2.30
Bovine papilloma virus-transformed cells contain multiple E2 proteins. Proc Natl Acad Sci U S A (1988) 2.29
Activation of the c-myb locus by viral insertional mutagenesis in plasmacytoid lymphosarcomas. Science (1984) 2.28
Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol (2001) 2.28
Restriction endonuclease mapping of ecotropic murine leukemia viral DNAs: size and sequence heterogeneity of the long terminal repeat. Virology (1981) 2.25
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology (2000) 2.25
Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis (1995) 2.21